ImmunoVaccine Technologies Completes Scale-Up of VacciMax® to Commercially Relevant Scale
News Nov 30, 2007
ImmunoVaccine Technologies Inc. (IVT) announced that it has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax®. This work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications.
The manufacturing development was performed at Dalton Pharma Services, a Health Canada and GMP compliant pharmaceutical manufacturing and development company. The results show that IVT's vaccine delivery platform can be produced on a commercial scale.
IVT's product, VacciMax®, is a vaccine-enhancement platform comprised of a special emulsion of liposomes, antigens, adjuvants and oil. To prepare VacciMax® for human cancer clinical trials, IVT has been developing its platform to meet all regulatory requirements including manufacturing in a GMP setting.
The ability to scale-up, under GMP or good manufacturing practices, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax® at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.
"We are pleased to collaborate with IVT and wish to congratulate the entire team on meeting such an important milestone. The successful scale-up of VacciMax® was a direct result of the Dalton and IVT teams' strong technical capabilities and project management skills," remarked Peter Pekos, President and CEO of Dalton Pharma Services.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Sciformix Corporation Collaborates with Oracle Health SciencesNews
New collaboration enables faster and more informed drug safety decisions.READ MORE